Provided by Tiger Fintech (Singapore) Pte. Ltd.

Werewolf Therapeutics, Inc.

0.6983
-0.0943-11.90%
Post-market: 0.73320.0349+5.00%19:55 EDT
Volume:349.88K
Turnover:256.43K
Market Cap:31.30M
PE:-0.43
High:0.8201
Open:0.7811
Low:0.6951
Close:0.7926
Loading ...

Werewolf Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
31 Mar

Promising Investment in Werewolf Therapeutics: Strong Financials and Strategic Partnerships Drive Growth Prospects

TIPRANKS
·
13 Mar

Analysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)

TIPRANKS
·
13 Mar

Werewolf Therapeutics Faces Geopolitical Risks Amid Changing Trade Policies with China

TIPRANKS
·
12 Mar

Werewolf Therapeutics Q4 2024 GAAP EPS $(0.46) Misses $(0.42) Estimate, As Of December 31, 2024, Cash And Cash Equivalents Were $111M, Expected To Provide Cash Runway Into Q2 Of 2026

Benzinga
·
11 Mar

Werewolf Therapeutics to Present at the 2025 Leerink Partners Global Biopharma Conference

GlobeNewswire
·
04 Mar

Pacira (PCRX) Tops Q4 Earnings Estimates

Zacks
·
28 Feb

Werewolf Therapeutics Appoints Anil Singhal to Board

TIPRANKS
·
24 Feb

Werewolf Therapeutics appoints Anil Singhal to board of directors

TIPRANKS
·
24 Feb

Werewolf Therapeutics Appoints Anil Singhal, Ph.d., to Its Board of Directors

THOMSON REUTERS
·
24 Feb

Press Release: Werewolf Therapeutics Appoints Anil Singhal, Ph.D., to its Board of Directors

Dow Jones
·
24 Feb

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch

Simply Wall St.
·
12 Feb

Werewolf Therapeutics price target lowered to $4 from $12 at JMP Securities

TIPRANKS
·
14 Jan

Buy Rating Affirmed for Werewolf Therapeutics Amid Strategic Advancements and Strong Financial Position

TIPRANKS
·
14 Jan

Werewolf Therapeutics provides business update, highlights 2025 outlook

TIPRANKS
·
13 Jan

Werewolf Therapeutics Inc - Data From Wtx-124 Monotherapy Trial Expected in H1 2025

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Inc - Data From Wtx-124 Combo Trial Expected in Q4 2025

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Inc - Cash Runway Expected Through Q2 2026

THOMSON REUTERS
·
13 Jan

Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook

GlobeNewswire
·
13 Jan